|
1
|
Menna P, Recalcati S, Cairo G and Minotti
G: An introduction to the metabolic determinants of anthracycline
cardiotoxicity. Cardiovasc Toxicol. 7:80–85. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lipshultz SE, Karnik R, Sambatakos P,
Franco VI, Ross SW and Miller TL: Anthracycline-related
cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol.
29:103–112. 2014. View Article : Google Scholar
|
|
3
|
Spallarossa P, Garibaldi S, Altieri P,
Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero
A, Patrone F, et al: Carvedilol prevents doxorubicin-induced free
radical release and apoptosis in cardiomyocytes in vitro. J Mol
Cell Cardiol. 37:837–846. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Renaud J, Bournival J, Zottig X and
Martinoli MG: Resveratrol protects DAergic PC12 cells from high
glucose-induced oxidative stress and apoptosis: Effect on p53 and
GRP75 localization. Neurotox Res. 25:110–123. 2014. View Article : Google Scholar :
|
|
5
|
Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu
HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12
cells from high glucose-induced neurotoxicity Via PI3K/Akt/FoxO3a
pathway. Cell Mol Neurobiol. 35:513–522. 2015. View Article : Google Scholar
|
|
6
|
Das S, Falchi M, Bertelli A, Maulik N and
Das DK: Attenuation of ischemia/reperfusion injury in rats by the
anti-inflammatory action of resveratrol. Arzneimittelforschung.
56:700–706. 2006.
|
|
7
|
Tatlidede E, Sehirli O, Velioğlu-Oğünc A,
Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S and Sener G:
Resveratrol treatment protects against doxorubicin-induced
cardiotoxicity by alleviating oxidative damage. Free Radic Res.
43:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: Molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rezk YA, Balulad SS, Keller RS and Bennett
JA: Use of resveratrol to improve the effectiveness of cisplatin
and doxorubicin: Study in human gynecologic cancer cell lines and
in rodent heart. Am J Obstet Gynecol. 194:e23–e26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park DG: Antichemosensitizing effect of
resveratrol in cotreatment with oxaliplatin in HCT116 colon cancer
cell. Ann Surg Treat Res. 86:68–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H,
Chen W, Shen T, Han X and Huang S: Hydrogen peroxide inhibits mTOR
signaling by activation of AMPKalpha leading to apoptosis of
neuronal cells. Lab Invest. 90:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Towler MC and Hardie DG: AMP-activated
protein kinase in metabolic control and insulin signaling. Circ
Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and
Lu PH: Activation of AMP-activated protein kinase contributes to
doxorubicin-induced cell death and apoptosis in cultured myocardial
H9c2 cells. Cell Biochem Biophys. 60:311–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okoshi R, Ozaki T, Yamamoto H, Ando K,
Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H:
Activation of AMP-activated protein kinase induces p53-dependent
apoptotic cell death in response to energetic stress. J Biol Chem.
283:3979–3987. 2008. View Article : Google Scholar
|
|
15
|
Liu J, Mao W, Ding B and Liang CS:
ERKs/p53 signal transduction pathway is involved in
doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am
J Physiol Heart Circ Physiol. 295:H1956–H1965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C
and Feng J: Hydrogen sulfide attenuates doxorubicin-induced
cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells.
Int J Mol Med. 31:644–650. 2013.PubMed/NCBI
|
|
17
|
Gu J, Hu W and Zhang DD: Resveratrol, a
polyphenol phytoalexin, protects against doxorubicin-induced
cardiotoxicity. J Cell Mol Med. 19:2324–2328. PubMed/NCBI
|
|
18
|
Wang X, Wang XL, Chen HL, Wu D, Chen JX,
Wang XX, Li RL, He JH, Mo L, Cen X, et al: Ghrelin inhibits
doxorubicin cardiotoxicity by inhibiting excessive autophagy
through AMPK and p38-MAPK. Biochem Pharmacol. 88:334–350. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D,
Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide
protects against doxorubicin-induced inflammation and cytotoxicity
by inhibiting p38MAPK/NFkB pathway in H9c2 cardiac cells. Cell
Physiol Biochem. 32:1668–1680. 2013.
|
|
20
|
Das DK, Mukherjee S and Ray D: Erratum to:
Resveratrol and red wine, healthy heart and longevity. Heart Fail
Rev. 16:425–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oktem G, Uysal A, Oral O, Sezer ED,
Olukman M, Erol A, Akgur SA and Bilir A: Resveratrol attenuates
doxorubicin-induced cellular damage by modulating nitric oxide and
apoptosis. Exp Toxicol Pathol. 64:471–479. 2012. View Article : Google Scholar
|
|
22
|
Shirwany NA and Zou MH: AMPK: A cellular
metabolic and redox sensor. A minireview. Front Biosci (Landmark
Ed). 19:447–474. 2014. View
Article : Google Scholar
|
|
23
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang S, Song P and Zou MH: Inhibition of
AMP-activated protein kinase alpha (AMPKα) by doxorubicin
accentuates genotoxic stress and cell death in mouse embryonic
fibroblasts and cardiomyocytes: Role of p53 and SIRT1. J Biol Chem.
287:8001–8012. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jones RG, Plas DR, Kubek S, Buzzai M, Mu
J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase
induces a p53-dependent metabolic checkpoint. Mol Cell. 18:283–293.
2005. View Article : Google Scholar : PubMed/NCBI
|
